X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ACTAVIS (US) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   ACTAVIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
ACTAVIS
Dec-14
PANACEA BIOTECH/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs14919,612-   
Low Rs8211,962-   
Sales per share (Unadj.) Rs84.13,531.5-  
Earnings per share (Unadj.) Rs-18.3-440.7-  
Cash flow per share (Unadj.) Rs-6.7324.0-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.77,659.7-  
Shares outstanding (eoy) m61.25265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.44.5 30.7%   
Avg P/E ratio x-6.3-35.8 17.6%  
P/CF ratio (eoy) x-17.248.7 -35.4%  
Price / Book Value ratio x1.42.1 66.9%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0744,197,775 0.2%   
No. of employees `0002.821.6 12.7%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.143,473.5 4.3%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.7-5,425.0 7.5%   
INCOME DATA
Net Sales Rs m5,154939,027 0.5%  
Other income Rs m100-2,344 -4.3%   
Total revenues Rs m5,254936,684 0.6%   
Gross profit Rs m-766120,631 -0.6%  
Depreciation Rs m711203,334 0.3%   
Interest Rs m1,50329,619 5.1%   
Profit before tax Rs m-2,881-114,665 2.5%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-8,411 -21.1%   
Tax Rs m17-5,895 -0.3%   
Profit after tax Rs m-1,121-117,181 1.0%  
Gross profit margin %-14.912.8 -115.7%  
Effective tax rate %-0.65.1 -11.3%   
Net profit margin %-21.8-12.5 174.4%  
BALANCE SHEET DATA
Current assets Rs m3,810494,747 0.8%   
Current liabilities Rs m8,365360,816 2.3%   
Net working cap to sales %-88.414.3 -619.7%  
Current ratio x0.51.4 33.2%  
Inventory Days Days15658 268.4%  
Debtors Days Days6766 101.4%  
Net fixed assets Rs m14,480114,665 12.6%   
Share capital Rs m610-   
"Free" reserves Rs m9030-   
Net worth Rs m5,1272,036,716 0.3%   
Long term debt Rs m5,8321,067,279 0.5%   
Total assets Rs m19,4333,732,629 0.5%  
Interest coverage x-0.9-2.9 31.9%   
Debt to equity ratio x1.10.5 217.1%  
Sales to assets ratio x0.30.3 105.4%   
Return on assets %2.0-2.3 -83.7%  
Return on equity %-21.9-5.8 380.1%  
Return on capital %3.6-3.0 -120.8%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m599161,249 0.4%  
From Investments Rs m-438-386,092 0.1%  
From Financial Activity Rs m-303216,928 -0.1%  
Net Cashflow Rs m-141-7,915 1.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: NOVARTIS  SANOFI INDIA  DIVIS LABORATORIES  LUPIN LTD  SHASUN PHARMA  



Today's Market

Sensex Trades Marginally Higher; Yes Bank & Tata Motors Top Gainers(12:30 pm)

Share markets in India are presently trading on a positive note. Sectoral indices are trading on a positive note with stocks in the realty sector.

Related Views On News

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Nov 19, 2018 02:49 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - JUBILANT LIFE SCIENCES COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS